A Trifecta in the Management of Neurofibromatosis Type 1 Plexiform Neurofibromas: Patient Voices, Systemic Therapy, and Multidisciplinary Collaboration
Released On
March 31, 2025
Expires On
March 31, 2026
Media Type
Internet
Completion Time
90 minutes
Specialty
Dermatology, Genetics, Hematology-Oncology, Neurology, Pediatrics, Surgery
Topic(s)
Oncology, Neurofibromatosis Type 1, Plexiform Neurofibromas
CME INFO
A Trifecta in the Management of Neurofibromatosis Type 1 Plexiform Neurofibromas: Patient Voices, Systemic Therapy, and Multidisciplinary Collaboration
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC (PQHE), in collaboration with National Organization for Rare Disorders (NORD), NF Network and Children's Tumor Foundation.
Acknowledgement
This activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.
Date of Release/Expiration
This activity was released on March 31, 2025, and is valid until March 31, 2026. Requests for credit must be made no later than March 31, 2026.
Credit Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credits™
Target Audience
The educational design of this activity addresses the needs of medical oncologists, neuro-oncologists, dermato-oncologists, pediatricians, neurologists, surgeons, advanced practice providers (NPs and PAs), dermatologists, and geneticists involved in the management of pediatric and adult patients with NF1-PN.
Program Overview
Peripheral nerve sheath tumors or plexiform neurofibromas (PNs) occur in approximately 30%-50% of children and adults with neurofibromatosis type 1 (NF1). Treatment with MEK inhibitors achieved tumor volume reduction and symptom improvement in children and adults in clinical trials. To provide the best possible care for patients with NF1-PN, clinicians must be aware of the clinical data on MEK inhibitors and be able to select patients who will benefit from that treatment. Explore three educational modules and learn more about the rationale for MEK inhibitors and the efficacy of established and emerging therapies, adverse events, and optimizing collaboration among members of the multidisciplinary care team for diagnosis, treatment, symptom management, and monitoring of patients with this disease. Patient/caregiver interviews will also highlight the patient/caregiver experience and perspectives on diagnosis, treatment, and impact of NF1-PN on daily life.
Educational Objectives
After completing this activity, the participant should be better able to:
- Review the rationale and mechanism of action for MEK inhibitor therapies in NF1-PN
- Evaluate efficacy data from practice-changing clinical trials on new and emerging MEK inhibitor therapies for inoperable NF1-PN
- Discuss adverse events associated with MEK-inhibitor therapies and approaches to monitor and mitigate those adverse events
- Outline strategies to individualize treatment plans for patients with NF1-PN through multidisciplinary care
Faculty
Michael J. Fisher, MD
Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology
Professor of Pediatrics
Division of Oncology
The Children’s Hospital of Philadelphia
Carlos Romo, MD
Assistant Professor of Neurology, Oncology and Medicine
Director of Clinical Research, The Neurofibromatosis Therapeutic Acceleration Program
Johns Hopkins University School of Medicine
Oluwaseun O. Akinduro, MD
Assistant Professor of Neurosurgery
Principal Investigator of Akinduro Spinal Oncology Laboratory
Mayo Clinic
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Continuing Education
Global Education Group designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete
This activity should take approximately 90 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Technical Support
For any technical issues or issues with your CME Certificate, please contact MedLive at 877-394-1306 or at [email protected].